A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
Clinical trial NCT06008353 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06008353
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-01-18
- Primary completion
- 2026-08-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.